EP3355877A4 - COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF - Google Patents

COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF Download PDF

Info

Publication number
EP3355877A4
EP3355877A4 EP16852276.1A EP16852276A EP3355877A4 EP 3355877 A4 EP3355877 A4 EP 3355877A4 EP 16852276 A EP16852276 A EP 16852276A EP 3355877 A4 EP3355877 A4 EP 3355877A4
Authority
EP
European Patent Office
Prior art keywords
urination
frequency
reducing
composition
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16852276.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3355877A1 (en
Inventor
David A. Dill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellesley Pharmaceuticals LLC
Original Assignee
Wellesley Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/870,676 external-priority patent/US10596127B2/en
Application filed by Wellesley Pharmaceuticals LLC filed Critical Wellesley Pharmaceuticals LLC
Publication of EP3355877A1 publication Critical patent/EP3355877A1/en
Publication of EP3355877A4 publication Critical patent/EP3355877A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16852276.1A 2015-09-30 2016-08-29 COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF Withdrawn EP3355877A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/870,676 US10596127B2 (en) 2013-03-14 2015-09-30 Composition for reducing the frequency of urination, method of making and use thereof
PCT/US2016/049246 WO2017058436A1 (en) 2015-09-30 2016-08-29 Composition for reducing the frequency of urination, method of making and use thereof

Publications (2)

Publication Number Publication Date
EP3355877A1 EP3355877A1 (en) 2018-08-08
EP3355877A4 true EP3355877A4 (en) 2019-05-15

Family

ID=58424324

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16852276.1A Withdrawn EP3355877A4 (en) 2015-09-30 2016-08-29 COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF

Country Status (7)

Country Link
EP (1) EP3355877A4 (ko)
JP (1) JP2018529710A (ko)
KR (1) KR20180066113A (ko)
CN (1) CN108430465A (ko)
AU (1) AU2016331879A1 (ko)
SG (1) SG11201805527QA (ko)
WO (1) WO2017058436A1 (ko)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119878B2 (en) * 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
AU748359B2 (en) * 1998-05-15 2002-06-06 Chugai Seiyaku Kabushiki Kaisha Controlled-release formulations
US20030194430A1 (en) * 2002-04-10 2003-10-16 Miller Frederick H. Process for encapsulating multi-phase, multi-compartment capsules for therapeutic compositions
DE60313603T2 (de) * 2002-04-24 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
KR20090037930A (ko) * 2006-07-11 2009-04-16 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 조절 방출 제형
TWI609702B (zh) * 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
JP2015503583A (ja) * 2012-01-04 2015-02-02 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための延長放出製剤およびその使用の方法
CN103191430A (zh) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 用于缓解尿频的缓释制剂及其使用方法
CN107569690A (zh) * 2012-01-04 2018-01-12 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
MX2014011128A (es) * 2012-03-19 2015-08-10 Wellesley Pharmaceuticals Llc Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
CN107661326A (zh) * 2012-07-27 2018-02-06 韦尔斯利医药有限公司 用于遗尿的药物制剂及其使用方法
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
BR102013020508B1 (pt) * 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119878B2 (en) * 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
EP3355877A1 (en) 2018-08-08
JP2018529710A (ja) 2018-10-11
WO2017058436A1 (en) 2017-04-06
KR20180066113A (ko) 2018-06-18
SG11201805527QA (en) 2018-07-30
CN108430465A (zh) 2018-08-21
AU2016331879A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
EP3626803A4 (en) COMPOSITION AND METHOD FOR PRODUCING THE COMPOSITION
EP3717484A4 (en) PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT
EP3142625A4 (en) Flushable wipe and method of forming the same
EP3104865A4 (en) Micro-organoids, and methods of making and using the same
EP3337823A4 (en) SUPPORTING BIN COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3356308A4 (en) POROUS PARTICLES ON CALCIUMSILICATE BASE, COMPOSITION, PROCESS FOR THE PREPARATION AND USE THEREOF
EP3234060A4 (en) Hydraulic fracturing composition, method for making and use of same
EP3594312A4 (en) COMPOSITION, PROCESS FOR ITS PRODUCTION AND ASSOCIATED USE
EP2978409A4 (en) Ophthalmic composition, method for preparing the same, and use of the same
EP3166892A4 (en) Scale-inhibition compositions and methods of making and using the same
EP3373910A4 (en) ECHINOMYCIN FORMULATION, METHOD FOR MANUFACTURING THE SAME, AND METHOD OF USING THE SAME
EP3117827A4 (en) Composition for vagina and use of the composition
EP3516127A4 (en) STRUCTURE AND MANUFACTURING METHOD THEREOF
EP3476872A4 (en) ELECTROLYTE MATERIAL, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
GB2572610B (en) Composition, methods for its production, and its use
EP3535434A4 (en) COBALT COMPOUNDS, METHOD OF MANUFACTURING AND METHOD OF USING THEREOF
EP3681491A4 (en) PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
EP3510134A4 (en) CLEANING COMPOSITION, MANUFACTURING METHOD THEREOF AND USE THEREOF
EP3551619A4 (en) COMPOSITIONS WITH METHYLPHENIDATE PRODRUGS, METHOD FOR THE PRODUCTION AND USE THEREOF
EP3227298A4 (en) Process for the preparation of baricitinib and an intermediate thereof
EP3530650A4 (en) CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF
EP3356480A4 (en) STAINLESS AQUEOUS COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
EP3341006A4 (en) COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
EP3334730A4 (en) Pyrrolomycins and methods of using the same
EP3685845A4 (en) COMPOSITION AND MANUFACTURING PROCESS FOR IT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180424

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190412

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/58 20060101ALI20190408BHEP

Ipc: A61K 9/50 20060101ALI20190408BHEP

Ipc: A61P 7/12 20060101ALI20190408BHEP

Ipc: A61P 7/00 20060101ALI20190408BHEP

Ipc: A61K 45/06 20060101ALI20190408BHEP

Ipc: A61K 31/19 20060101AFI20190408BHEP

Ipc: A61K 9/00 20060101ALI20190408BHEP

Ipc: A61K 31/167 20060101ALI20190408BHEP

Ipc: A61K 31/18 20060101ALI20190408BHEP

Ipc: A61K 31/192 20060101ALI20190408BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191112